drugset / Trial / NCT05991362
A Phase I Study of GFH312 in Healthy Chinese Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
The aim of this study was to evaluate the pharmacokinetic profile and observe the safety of GFH312 after single and multiple administrations in healthy Chinese subjects.
Timeline
- Start
- 2022-11-29
- Primary completion
- 2023-02-13
- Completion
- 2023-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GFH312 | Small molecule | 100 mg | Oral |
| Subject | GFH312 | Small molecule | 120 mg | Oral |
| Subject | GFH312 | Small molecule | 200 mg | Oral |
Indications
No indication recorded.